Dr. Burstein on the Follow-Up of APT Trial for HER2+ Breast Cancer

Harold J. Burstein, MD, PhD
Published: Thursday, Jun 22, 2017



Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the 7-year follow-up of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

In the initial results, there was a disease-free survival of 97%, explains Burstein. Those results were validated following the 7-year follow-up. Additionally, the instance of distant metastatic recurrence is low.

These follow-up results demonstrate that the patients on this trial have seen significant benefits, states Burstein.
 
SELECTED
LANGUAGE


Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the 7-year follow-up of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

In the initial results, there was a disease-free survival of 97%, explains Burstein. Those results were validated following the 7-year follow-up. Additionally, the instance of distant metastatic recurrence is low.

These follow-up results demonstrate that the patients on this trial have seen significant benefits, states Burstein.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication
x